Crizotinib

KRAS proto-oncogene, GTPase ; Homo sapiens







12 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34568053 ALK Rearrangement-Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report. 2021 1
2 30352902 Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. 2019 Feb 15 1
3 30412912 Enhancing the Radiation Response in KRAS Mutant Colorectal Cancers Using the c-Met Inhibitor Crizotinib. 2019 Feb 4
4 30072474 Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer. 2018 Dec 1 4
5 28007627 Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). 2017 Apr 1
6 28601386 Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment. 2017 Nov 2
7 26381283 EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect. 2016 Jan 1
8 26898615 K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature. 2016 Mar 2
9 27040858 EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient. 2016 May 1
10 25691052 Activation of RAS family members confers resistance to ROS1 targeting drugs. 2015 Mar 10 1
11 26517679 Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells. 2015 Nov 24 1
12 25232318 Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary. 2014 May 1